Myogen Files Shelf Registration Statement

June 6, 2005

Myogen, a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, announced that it filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow Myogen to sell from time to time up to $125 million of its common stock, preferred stock, depository shares, debt securities or warrants.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=245551)